Literature DB >> 34354555

Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer.

Mirza Zain Baig1, Alexandra Filkins2, Muhammad Khan3, Muhammad Wasif Saif3, Hassan Aziz4.   

Abstract

BACKGROUND: The effects of adjuvant radiation therapy on pancreatic cancer outcomes after resection are not well defined in the literature.
METHODS: We abstracted data from the Surveillance, Epidemiology, and End Result (SEER) database to explore the impact of adjuvant radiation on cancer-specific survival in pancreatic cancer patients who received surgical resection.
RESULTS: A total of 10,224 patients met our inclusion criteria with 6768 (66.2%) patients treated with surgery only and 3456 (33.8%) treated with surgery plus adjuvant radiation. Surgery followed by adjuvant radiation was associated with significantly improved survival (HR: 0.753, CI: 0.718-0.789, p<0.001). Additionally, female gender and married status were both independently associated with better survival (p<0.05), while advanced age, Caucasian race, higher TNM stage, and higher grade had worse survival outcomes (p<0.05) Asian and Spanish-Hispanic-Latino patients were less likely to receive adjuvant radiotherapy (p<0.05).
CONCLUSION: Adjuvant radiation was associated with significantly improved survival after resection for pancreatic cancer. There are significant differences in the patient populations who receive adjuvant radiation.

Entities:  

Keywords:  Pancreas cancer; Pancreatic neoplasms; Radiation; Radiosurgery; Radiotherapy; Stereotactic; Stereotactic body radiation therapy (SBRT)

Year:  2021        PMID: 34354555      PMCID: PMC8336069     

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  21 in total

1.  Neoadjuvant Chemoradiation Therapy Is Associated with Adverse Outcomes in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Cancer.

Authors:  Hassan Aziz; Muhammad Zeeshan; Tun Jie; Felipe B Maegawa
Journal:  Am Surg       Date:  2019-11-01       Impact factor: 0.688

2.  Cancer of the pancreas. 50 years of surgery.

Authors:  B Gudjonsson
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

3.  Prognostic factors for survival in pancreatic cancer: a population-based study.

Authors:  Mohamad A Eloubeidi; Renee A Desmond; C Mel Wilcox; Reda J Wilson; Pavan Manchikalapati; Mona M Fouad; Isam Eltoum; Selwyn M Vickers
Journal:  Am J Surg       Date:  2006-09       Impact factor: 2.565

4.  Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy.

Authors:  J Tepper; G Nardi; H Sutt
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

5.  Lobectomy is superior to segmentectomy for peripheral high grade non-small cell lung cancer ≤2 cm.

Authors:  Mirza Zain Baig; Syed S Razi; Joanna F Weber; Cliff P Connery; Faiz Y Bhora
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

6.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Authors:  M H Kalser; S S Ellenberg
Journal:  Arch Surg       Date:  1985-08

7.  Adjuvant therapy of resected adenocarcinoma of the pancreas.

Authors:  R Whittington; M P Bryer; D G Haller; L J Solin; E F Rosato
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-10       Impact factor: 7.038

8.  Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data.

Authors:  Krisha J Opfermann; Amy E Wahlquist; Elizabeth Garrett-Mayer; Ravi Shridhar; Leander Cannick; David T Marshall
Journal:  Am J Clin Oncol       Date:  2014-04       Impact factor: 2.339

9.  Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses.

Authors:  Hassan Aziz; Yuri Genyk; Muhammad Wasif Saif; Alexandra Filkins; Rick Selby; Mohd Raashid Sheikh
Journal:  Cancer Med J       Date:  2021-04-01

Review 10.  Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy.

Authors:  William A Hall; Karyn A Goodman
Journal:  Radiat Oncol       Date:  2019-06-26       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.